probiot
live
microorgan
benefici
effect
human
health
abil
counteract
infect
differ
locat
bodi
clinic
trial
shown
probiot
use
prevent
therapeut
agent
upper
respiratori
tract
infect
urti
otiti
mechan
properti
allow
aggreg
compet
pathogen
nutrient
space
attach
host
cell
consequ
directli
antagon
pathogen
thu
exert
benefici
effect
without
directli
affect
metabol
host
overview
probiot
trait
test
date
clinic
trial
prevent
treatment
urti
otiti
present
review
mechan
properti
respiratori
tract
well
locat
also
cite
speci
interest
vitro
properti
toward
pharyng
cell
common
respiratori
pathogen
also
includ
potenti
safeti
risk
cite
speci
discuss
review
could
help
screen
probiot
strain
specif
mechan
properti
suscept
posit
effect
clinic
trial
urti
discov
middl
twentieth
centuri
antibiot
offer
promis
effici
cheap
treatment
bacteri
infect
even
possibl
elimin
infecti
diseas
pathogen
howev
found
way
surviv
develop
resist
rang
antibiot
make
treatment
diseas
difficult
also
present
seriou
threat
immunodepriv
popul
altern
antimicrobi
approach
develop
probiot
gain
special
interest
last
year
accord
latest
definit
world
health
organ
probiot
live
microorgan
administ
adequ
amount
confer
health
benefit
host
faowho
probiot
treatment
aim
direct
composit
microbiota
potenti
harm
microbiota
would
benefici
host
probiot
use
mean
prevent
reduc
risk
overgrowth
potenti
pathogen
bacteria
thu
suppress
colon
latter
ouwehand
et
al
also
aim
restor
lost
bacteria
metabol
activ
colon
organ
stimul
immun
respons
kalliomaki
isolauri
probiot
shown
benefici
differ
site
human
bodyor
caviti
respiratori
tract
gastrointestin
tract
urogenit
tract
well
establish
posit
effect
treatment
diarrhoea
includ
antibiot
associ
travel
diarrhoea
vagin
function
gastrointestin
disord
review
see
allen
et
al
macphe
et
al
girardin
seidman
nowaday
variou
probiot
strain
commerci
aim
prevent
treat
type
diseas
human
clinic
trial
anim
studi
shown
probiot
could
broader
applic
could
also
use
prevent
treat
reliev
symptom
case
cari
periodont
allergi
atop
diseas
respiratori
infect
otiti
inflammatori
bowel
diseas
crohn
diseas
colorect
cancer
acut
gastroenter
lactos
intoler
cystiti
review
see
stamatova
meurman
stamatova
et
al
ozdemir
gupta
meijer
dieleman
yu
vitro
anim
studi
allow
elucid
properti
mode
action
benefici
microorgan
action
direct
host
pathogen
probiot
may
modul
host
innat
acquir
immun
respons
product
like
metabolit
cell
wall
compon
dna
may
increas
intestin
mucin
product
mack
et
al
may
produc
substanc
inhibit
pathogenslowmolecularweight
substanc
lowand
highmolecularweight
bacteriocin
antibiot
microcin
oelschlaeg
benefici
bacteria
also
exert
direct
mechan
effect
pathogen
mechan
properti
allow
antagon
compet
without
affect
metabol
neither
host
pathogen
competit
involv
adhes
bind
site
nutrient
space
lepargneur
rousseau
abil
adher
surfac
epitheli
cell
mucu
enabl
probiot
form
protect
layer
thu
block
contact
pathogen
host
cell
adhes
abil
also
allow
probiot
compet
pathogen
bacteria
bind
site
lepargneur
rousseau
bind
receptor
affin
probiot
higher
abil
displac
pathogen
furthermor
adher
probiot
occlud
access
recent
arriv
pathogen
epithelium
thu
exert
competit
exclus
otool
cooney
size
also
import
factor
larges
probiot
bacteria
could
exert
better
competit
exclus
pathogen
smallsiz
one
mask
specif
receptor
site
pathogen
microorgan
cell
surfac
steric
hindranc
merk
et
al
competit
nutrient
result
deplet
probiot
nutrient
environ
would
otherwis
avail
pathogen
addit
may
bind
render
unavail
pathogen
limit
substanc
iron
oelschlaeg
probiot
pathogen
also
compet
space
essenti
multipl
microorgan
alvarezolmo
oberhelman
anoth
desir
mechan
properti
probiot
capac
aggreg
among
autoaggreg
probiot
pathogen
coaggreg
autoaggreg
coaggreg
probiot
adequ
mass
achiev
necessari
microorgan
manifest
benefici
effect
collado
et
al
aggreg
also
enabl
format
barrier
protect
host
epithelium
colon
pathogen
moreov
abil
coaggreg
pathogen
allow
probiot
entrap
bori
et
al
et
al
properti
mode
action
probabl
involv
global
benefici
effect
exert
probiot
properti
mode
action
differ
among
probiot
strain
specif
moreov
mechan
properti
also
locat
specif
thu
singl
probiot
remedi
diseas
oelschlaeg
underlin
import
choos
appropri
strain
given
condit
upper
respiratori
tract
infect
urti
repres
common
acut
ill
patient
outset
account
consult
gener
practic
bourk
urti
includ
rhiniti
rhinosinus
rhinopharyng
also
call
common
cold
pharyng
epiglott
laryng
also
includ
otiti
review
even
though
otiti
affect
respiratori
tract
infect
upper
respiratori
tract
extend
ear
eustachian
tube
urti
viral
bacteri
origin
common
virus
caus
urti
rhinovirus
coronavirus
parainfluenza
influenza
virus
among
bacteria
caus
urti
frequent
pathogen
group
streptococci
mycoplasma
pneumonia
chlamidia
pneumonia
corynebacterium
diphteria
staphylococcu
aureu
streptococcu
pneumonia
bourk
case
pharyng
origin
infect
viral
case
children
case
adult
bacteri
origin
account
case
children
case
adult
pichichero
urti
bacteri
origin
commonli
treat
antibiot
mention
earlier
howev
antibiotherapi
present
drawback
especi
occurr
resist
bacteria
altern
method
treatment
urti
could
use
probiot
aim
review
present
probiot
speci
test
date
clinic
trial
prevent
treatment
urti
otiti
tabl
bacteria
yeast
speci
found
mainli
focus
speci
mechan
properti
probiot
mechan
properti
immun
stimulatori
effect
also
includ
trial
conduct
subject
heavi
physic
train
well
trial
employ
synbiot
exclud
vitro
anim
studi
explain
mechan
properti
mode
action
test
probiot
tabl
summar
mechan
properti
probiot
upper
respiratori
tract
well
site
bodi
identifi
clinic
trial
address
effect
probiot
urti
otiti
four
trial
shown
signific
differ
outcom
measur
probiot
placebo
group
tano
et
al
weizman
et
al
hatakka
et
al
taipal
et
al
moreov
clinic
trial
conduct
hatakka
colleagu
show
increas
preval
moraxella
catarrhali
probiot
group
trial
report
benefici
effect
probiot
improv
specif
sicknessrel
outcom
measur
varieti
probiot
strain
use
clinic
trial
chosen
includ
three
probiot
speci
lactobacillu
casei
lact
helveticu
lactococcu
lacti
review
test
clinic
trial
effect
urti
howev
vitro
studi
shown
possess
mechan
properti
allow
antagon
respiratori
tract
pathogen
could
thu
potenti
probiot
candid
futur
clinic
studi
commonli
use
strain
lact
rhamnosu
urti
trial
gg
alon
associ
bifidobacterium
animali
subsp
lacti
probiot
reduc
incid
respiratori
infect
acut
otiti
media
children
well
use
antibiot
hatakka
et
al
rautava
et
al
combin
two
probiot
may
reduc
colon
respiratori
pathogen
local
inhibit
well
immunomodul
throughout
common
mucosaassoci
immun
system
rautava
et
al
hojsak
colleagu
demonstr
reduc
risk
urti
upon
consumpt
lact
rhamnosu
gg
also
reduct
total
number
day
respiratori
symptom
hojsak
et
al
combin
strep
thermophilu
lact
acidophilu
bifidobacterium
sp
lact
rhamnosu
gg
shown
reduc
nasal
colon
pathogen
staph
aureu
strep
pneumonia
adult
immunostimulatori
mechan
may
involv
gluck
gebber
anoth
clinic
trial
howev
strain
gg
associ
bif
breve
propionibacterium
freudenreichii
subsp
shermanii
js
show
benefici
effect
decreas
occurr
recurr
acut
otiti
media
nasopharyng
carriag
hatakka
et
al
mechan
properti
lact
rhamnosu
among
extens
studi
among
probiot
differ
strain
probiot
mechan
effect
respiratori
tract
intestin
urogenit
oral
caviti
pathogen
lactobacillu
rhamnosu
strain
show
follow
mechan
properti
autoaggreg
coaggreg
adher
competit
exclus
competit
steric
hindranc
competit
adhes
competit
bind
site
vitro
lact
rhamnosu
gg
good
bind
capac
human
pharyng
cell
guglielmetti
et
al
antagon
respiratori
tract
pathogen
strep
pyogen
guglielmetti
et
al
vitro
studi
shown
strain
gg
antimicrobi
activ
group
streptococci
antagonist
activ
may
exert
inhibit
cell
invas
pathogen
probabl
competit
fn
bind
sitesa
fibronectin
requir
effici
entri
epitheli
cell
princiv
et
al
strain
isol
oral
caviti
healthi
thai
volunt
antagon
staph
aureu
sookkhe
et
al
lactobacillu
rhamnosu
capac
coaggreg
cariogen
pathogen
strep
mutan
strep
sobrinu
twetman
et
al
strain
gg
coaggreg
intestin
pathogen
escherichia
coli
salmonella
enterica
collado
et
al
interfer
adhes
steric
hindranc
lee
puong
strain
adher
buccal
epitheli
cell
salivaco
surfac
haukioja
et
al
stamatova
et
al
human
epitheli
intestin
cell
tuomola
salminen
colon
morelli
et
al
intestin
mucu
et
al
strain
also
adher
human
intestin
epitheli
cell
compet
intestin
pathogen
adher
cell
foresti
et
al
gopal
et
al
anoth
strain
adher
human
epitheli
intestin
cell
tuomola
salminen
strain
compet
vagin
pathogen
adhes
cervic
vagin
cell
coudeyra
et
al
lactobacillu
rhamnosu
adher
vagin
epitheli
cell
coaggreg
vagin
pathogen
e
coli
gardnerella
vaginali
candida
albican
pascual
et
al
strain
adher
squamou
uroepitheli
cell
compet
uropathogen
competit
exclus
reid
et
al
reid
clinic
trial
involv
lact
acidophilu
ncfm
alon
combin
bif
animali
subsp
lacti
show
probiot
reduc
influenzalik
symptom
fever
rhinorrhoea
cough
incid
durat
antibiot
prescript
explan
given
author
explain
effect
leyer
et
al
strain
lact
acidophilu
along
lact
rhamnosu
gg
strep
thermophilu
bifidobacterium
sp
reduc
nasal
colon
pathogen
staph
aureu
strep
pneumonia
adult
possibl
immunostimulatori
mechan
gluck
gebber
lactobacillu
acidophilu
strain
possess
numer
mechan
properti
one
autoaggreg
bori
et
al
strain
ccug
coaggreg
cariogen
bacteria
strep
mutan
chauvier
et
al
coconni
et
al
bernet
et
al
tuomola
salminen
gopal
et
al
strain
also
adher
intestin
mucu
chauvier
et
al
bernet
et
al
gopal
et
al
strain
lb
inhibit
adhes
diarrhoeagen
enterotox
e
coli
brush
border
intestin
cell
coconni
et
al
compet
pathogen
steric
hindranc
attach
enterocyt
pathogen
receptor
reid
et
al
strain
inhibit
colon
intestin
monolay
e
coli
gopal
et
al
lactobacillu
acidophilu
strain
uo
inhibit
growth
certain
enteropathogen
salmonella
listeria
campylobact
fernandez
et
al
streptococcu
salivariu
bli
throat
guard
probiot
product
describ
natur
remedi
common
cold
flu
streptococcu
salivariu
reduc
halitosi
burton
et
al
masdea
et
al
press
commerci
probiot
oral
malodour
strain
capac
adher
human
epitheli
pharyng
cell
vitro
antagon
strep
pyogen
exclus
competit
guglielmetti
et
al
strain
also
inhibit
growth
c
albican
vitro
protect
mice
oral
cadidosi
ishijima
et
al
vitro
alon
combin
lact
helveticu
strain
adher
pharyng
epitheli
cell
antagon
strep
pyogen
modul
host
innat
immun
induc
potenti
protect
effect
tavern
et
al
strain
modul
growth
oral
bacteria
vitro
comelli
et
al
bifidobacterium
animali
subsp
lacti
alon
combin
lact
rhamnosu
gg
reduc
respiratori
infect
rautava
et
al
taipal
et
al
trial
conduct
rautava
collabor
associ
two
probiot
also
reduc
risk
earli
acut
otiti
media
well
use
antibiot
effect
may
mediat
via
reduct
colon
pathogen
local
inhibit
immunomodul
throughout
common
mucosaassoci
immun
system
rautava
et
al
howev
taipal
coauthor
report
differ
incid
otiti
media
use
antibiot
taipal
et
al
signific
differ
rate
durat
respiratori
ill
probiot
placebo
group
upon
administr
bif
animali
subsp
lacti
also
absent
trial
conduct
weizman
colleagu
weizman
et
al
bifidobacterium
animali
subsp
lacti
administ
alon
combin
lact
acidophilu
ncfm
anoth
clinic
trial
result
reduct
influenzalik
symptom
durat
antibiot
use
leyer
et
al
bifidobacterium
animali
subsp
lacti
abil
autoaggreg
strain
adher
brush
border
intestin
epitheli
cell
intestin
mucu
gopal
et
al
bifidobacterium
animali
subsp
lacti
coaggreg
e
coli
salm
enterica
collado
et
al
strain
exert
competit
exclus
intestin
pathogen
candela
et
al
clinic
trial
involv
lact
delbrueckii
subsp
bulgaricu
associ
strep
salivariu
subsp
thermophilu
show
reduc
risk
catch
common
cold
probiot
ingest
subsequ
vitro
studi
show
probiot
immunostimulatori
effect
makino
et
al
vitro
lact
delbrueckii
subsp
bulgaricu
strain
capac
autoaggreg
coaggreg
e
coli
aslim
et
al
number
strain
laboratori
collect
lb
lacti
bulgaria
adher
salivaco
surfac
stamatova
et
al
strain
bind
intestin
epitheli
cell
green
klaenhamm
strain
inhibit
cytotox
effect
adhes
pathogen
clostridium
difficil
cell
banerje
et
al
lactobacillu
paracasei
associ
lact
plantarum
heal
lower
incid
common
cold
episod
reduc
sever
pharyng
symptom
explan
given
author
effect
berggren
et
al
lactobacillu
casei
name
lact
paracasei
subsp
paracasei
accord
current
nomenclatur
contain
actimel
associ
strep
thermophilu
lact
delbrueckii
subsp
bulgaricu
consumpt
commerci
avail
ferment
probiot
dairi
drink
reduc
durat
urti
specif
rhinopharyng
guillemard
et
al
merenstein
et
al
even
though
explan
effect
given
author
guillemard
colleagu
observ
modul
immun
paramet
natur
killer
cell
activ
cytokin
secret
guillemard
et
al
lactobacillu
paracasei
coaggreg
cariogen
bacteria
strep
mutan
strep
sobrinu
twetman
et
al
strain
isol
oral
caviti
healthi
volunt
possess
high
capac
antagon
import
oral
pathogen
includ
staph
aureu
sookkhe
et
al
strain
adher
human
epitheli
intestin
cell
compet
adhes
salm
enterica
vitro
jankowska
et
al
strain
crl
adher
vagin
epitheli
cell
vitro
exert
competit
exclus
staph
aureu
zarat
nadermacia
clinic
trial
conduct
lact
plantarum
heal
associ
lact
paracasei
show
reduc
incid
durat
common
cold
episod
reduct
sever
pharyng
symptom
explan
effect
given
author
berggren
et
al
lactobacillu
plantarum
coaggreg
cariogen
bacteria
strep
mutan
strep
sobrinu
twetman
et
al
strain
also
adher
vitro
mucos
colon
cell
rectal
mucosa
patient
klarin
et
al
strain
bfe
capac
autoaggreg
adher
human
epitheli
intestin
cell
coaggreg
intestin
pathogen
vizoso
pinto
et
al
lactobacillu
plantarum
exert
competit
exclus
displac
salm
typhimurium
e
coli
candela
et
al
strain
adher
human
epitheli
intestin
cell
compet
adhes
clostridium
sporogen
enterococcu
faecali
ramiah
et
al
associ
lact
delbrueckii
subsp
bulgaricu
strep
thermophilu
reduc
risk
catch
common
cold
healthi
adult
elderli
subsequ
vitro
studi
show
probiot
immunostimulatori
effect
makino
et
al
streptococcu
thermophilu
combin
lact
rhamnosu
gg
lact
acidophilu
bifidobacterim
sp
reduc
nasal
colon
pathogen
bacteria
immunostimulatori
effect
suspect
action
gluck
gebber
velez
et
al
intestin
mucu
khalil
bifidobacterium
longum
sp
combin
lact
gasseri
pa
bif
bifidum
mf
reduc
durat
common
cold
episod
sever
symptom
clinic
trial
may
due
immun
stimulatori
effect
vrese
et
al
bifidobacterium
longum
possess
capac
autoaggreg
coaggreg
clostridia
vitro
vlkova
et
al
strain
adher
brush
border
intestin
cell
intestin
mucu
exert
competit
exclus
e
coli
salmonella
candela
et
al
strain
isol
gastric
juic
adher
intestin
epitheli
cell
et
al
bifidobacterium
bifidum
mf
associ
lact
gasseri
pa
b
longum
sp
reduc
durat
episod
common
cold
reduc
sever
symptom
immunostimulatori
effect
vrese
et
al
bifidobacterium
bifidum
capac
autoaggreg
well
coaggreg
clostridia
vitro
vlkova
et
al
studi
volunt
follow
vitro
analysi
show
coryn
isol
nare
healthi
volunt
prevent
elimin
colon
nasal
caviti
pathogen
staph
aureu
use
nonbacteriocinlik
mechan
strain
possess
aggreg
capac
possibl
compet
staph
aureu
attach
molecul
uehara
et
al
streptococcu
sanguini
test
seven
clinic
trial
one
clinic
trial
strain
ncimb
complet
almost
complet
resorpt
middl
ear
fluid
observ
children
secretori
otiti
media
author
suggest
stimul
antibacteri
immun
effector
mechan
rather
bacteri
interfer
might
respons
observ
clinic
effect
skovbjerg
et
al
associ
strep
miti
strep
sanguini
decreas
recurr
rate
group
streptococci
patient
acut
streptococc
pharyngotonsil
falck
et
al
combin
probiot
also
decreas
recurr
tonsil
patient
suffer
recurr
acut
streptococc
tonsil
pharyngotonsil
roo
et
al
roo
et
al
b
combin
strep
sanguini
strep
miti
strep
orali
strain
isol
open
eustachian
tube
healthi
children
decreas
recurr
otiti
media
roo
et
al
anoth
clinic
trial
combin
probiot
speci
isol
nasopharyng
healthi
children
benefici
effect
tano
et
al
vitro
strep
sanguini
strain
isol
open
eustachian
tube
healthi
children
capac
antagon
pathogen
includ
strep
pneumonia
h
influenza
mor
catarrhali
strep
pyogen
roo
et
al
strain
bind
human
oral
epitheli
cell
saliva
okahashi
et
al
okahashi
et
al
strain
inhibit
aggregatibact
actinomycetemcomitan
oral
bacterium
found
infect
oral
caviti
mainli
periodont
sliepen
et
al
effect
strep
miti
urti
test
six
clinic
trial
combin
strep
miti
strept
orali
strept
sanguini
strain
isol
nasopharyng
healthi
children
use
tano
colleagu
clinic
trial
show
signific
outcom
tano
et
al
contrari
upon
administr
strep
miti
strep
orali
strep
sanguini
strain
isol
open
eustachian
tube
healthi
children
roo
colleagu
observ
decreas
recurr
rate
group
streptococci
children
suffer
recurr
otiti
media
roo
et
al
four
clinic
trial
conduct
combin
strep
miti
strep
sanguini
strain
decreas
recurr
tonsil
observ
patient
acut
recurr
tonsil
pharyngotonsil
roo
et
al
roo
et
al
b
well
decreas
recurr
rate
group
streptococci
falck
et
al
vitro
strain
bm
reduc
adhes
inhibit
prevotella
gingivali
hoogmo
et
al
effect
strep
orali
studi
two
clinic
trial
employ
combin
strep
orali
strep
sanguini
strep
miti
one
clinic
trial
posit
outcom
signific
decreas
recurr
rate
group
streptococci
observ
treat
group
trial
use
strain
isol
open
eustachian
tube
healthi
children
roo
et
al
second
clinic
trial
employ
strain
isol
nasopharyng
healthi
children
show
posit
outcom
tano
et
al
vitro
strep
orali
strain
parker
booth
isol
nasopharyng
patient
undergo
adenoidectomi
either
hypertrophi
recurr
otiti
media
analys
strain
capac
antagon
inhibit
growth
pathogen
nasopharynx
includ
strep
pneumonia
h
influenza
mor
catarrhali
strep
pyogen
bernstein
et
al
lactobacillu
casei
test
clinic
trial
effect
urti
vitro
lact
casei
shirota
exhibit
high
bind
capac
salivaco
surfac
surviv
saliva
haukioja
et
al
strain
also
possess
antagonist
activ
strep
pyogen
exclus
guglielmetti
et
al
lactobacillu
casei
fyo
adher
human
intestin
epitheli
cell
tuomola
salminen
strain
shirota
compet
intestin
pathogen
e
coli
salm
enterica
probabl
steric
hindranc
lee
puong
lactobacillu
helveticu
adher
human
pharyng
cell
vitro
antagon
strep
pyogen
exclus
competit
adhes
site
cell
guglielmetti
et
al
probiot
use
clinic
trial
urti
lactococcu
lacti
subsp
cremori
viili
possess
high
bind
capac
human
pharyng
cell
antagon
strep
pyogen
guglielmetti
et
al
strain
adher
colon
cell
human
intestin
mucu
kimoto
et
al
strain
specifi
author
reduc
adhes
viabil
staph
aureu
vesterlund
et
al
clinic
trial
conduct
probiot
date
time
drawback
risk
unjustifi
antibiot
treatment
understood
patient
doctor
may
turn
probiot
safer
mean
prevent
treatment
diseas
present
probiot
employ
clinic
trial
aim
prevent
treat
urti
otiti
mani
bacteria
mechan
also
immun
stimulatori
effect
discuss
immun
properti
vast
topic
subject
present
review
follow
section
mechan
properti
probiot
discuss
probiot
report
review
lactic
acid
bacteria
belong
lact
lactococcu
bifidobacterium
famili
also
sever
strep
speci
import
aspect
consid
develop
probiot
product
safeti
larg
number
lactic
acid
bacteria
consid
safe
approv
efsa
introduct
food
chain
grant
posit
qp
statu
qualifi
presumpt
safeti
safeti
assess
system
base
four
paramet
establish
ident
bodi
knowledg
possibl
pathogen
end
use
microorgan
organ
grant
qp
statu
rais
safeti
concern
use
probiot
substanc
without
safeti
assess
satisfi
qualif
specifi
lack
posit
qp
statu
impli
microorgan
hazard
howev
must
undergo
full
safeti
assess
efsa
microorgan
might
approv
efsa
may
gain
gra
gener
recogn
safe
statu
fda
usa
case
strep
salivariu
also
approv
food
ingredi
australia
new
zealand
safeti
recent
assess
clinic
trial
show
intak
bacterium
well
toler
human
burton
et
al
speci
effect
urti
grant
posit
qp
statu
rare
case
presenc
predispos
factor
underli
diseas
immunocompromis
statu
earli
age
present
speci
associ
infect
efsa
import
underlin
case
extrem
rare
relat
consumpt
probiot
exampl
strep
miti
strep
orali
strep
sanguini
respons
rare
case
infecti
endocard
miyata
et
al
nyawo
et
al
renton
et
al
lactococcu
lacti
also
rare
caus
sever
infect
infecti
endocard
halldorsdottir
et
al
commonli
consum
bacterium
dairi
starter
consumpt
larg
quantiti
chees
ferment
milk
gener
safe
howev
deni
qp
statu
efsa
larg
major
herecit
clinic
trial
conduct
urti
otiti
show
posit
outcom
among
clinic
trial
present
review
posit
outcom
four
show
benefici
effect
use
probiot
moreov
six
clinic
trial
conduct
strep
miti
strep
orali
strep
sanguini
shown
posit
outcom
without
clinic
complic
search
probiot
strain
given
condit
aim
probiot
prepar
clearli
defin
prevent
infect
treatment
may
necessit
differ
mechan
properti
case
prevent
probiot
establish
microbiota
capabl
inhibit
andor
block
colon
pathogen
case
treatment
howev
probiot
need
confront
alreadi
establish
popul
pathogen
case
aggreg
adher
requir
properti
probiot
absenc
pathogen
probiot
would
adher
host
cell
protect
block
access
pathogen
pathogen
arriv
could
trap
coaggreg
thu
elimin
possibl
probiot
confer
complet
protect
infect
howev
could
help
fight
pathogen
thu
reduc
durat
sever
symptom
alreadi
infect
organ
desir
abil
probiot
exert
competit
exclus
higher
affin
bind
site
would
allow
exclud
attach
pathogen
could
subsequ
elimin
coaggreg
hand
strong
adher
host
cell
would
allow
probiot
occupi
free
space
epitheli
surfac
thu
could
slow
multipl
pathogen
compet
space
nutrient
case
urti
clinic
trial
destin
prevent
diseas
healthi
popul
prevent
recurr
diseasepron
patient
review
aim
underlin
import
mechan
properti
probiot
action
pathogen
special
interest
probiot
shown
effect
prevent
urti
otiti
properti
probiot
strain
specif
know
date
small
part
potenti
offer
friendli
bacteria
review
might
help
choic
probiot
speci
develop
novel
probiot
applic
herecit
speci
almost
half
lactic
bacteria
belong
lact
genu
lact
rhamnosu
lact
acidophilu
lact
delbrueckii
lact
paracasei
lact
plantarum
lact
casei
lact
helveticu
bifidobacterium
genu
bif
animali
b
longum
b
bifidum
speci
lact
rhamnosu
lact
acidophilu
extens
studi
compar
other
test
clinic
trial
extens
studi
speci
welldocu
mechan
properti
seem
offer
bigger
chanc
success
search
new
strain
mechan
properti
less
studi
probiot
less
well
known
potenti
underestim
final
could
also
interest
investig
less
frequent
use
urti
studi
streptococcu
genu
strep
salivariu
strep
miti
strep
orali
strep
sanguini
